Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993824 · ClinicalTrials.gov registry record · Phase 2
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00993824 is a Phase 2 study that has completed, run by HealthPartners Institute. The registered enrollment target is 21 participants.
The verdict
NCT00993824, a Phase 2 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo. The CGM data will determine the effect on glucose control of adding Welchol to an anti-diabetic medication regimen.
Interventions
- DRUG placebo
- DRUG colesevelam HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993824
The ClinicalTrials.gov registry entry for NCT00993824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00993824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00993824 about?
NCT00993824 is a clinical study titled "Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes". The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo. The CGM data will determine the effect on glucose control of adding Welchol to an anti-diabetic medication regimen.
What is the current status of trial NCT00993824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2009-09. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00993824?
The interventions under investigation include: placebo (DRUG), colesevelam HCl (DRUG).
Who is sponsoring clinical trial NCT00993824?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.